Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 591 | 39% |
| 2020 | 8 | 494 | 46% |
| 2021 | 11 | 509 | 51% |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in Maine; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 134 | 7,123−2.3%/yr | −2.3%/yr | 4.0 | 10% | 7,020 in 2030−0.2%/yr |
| Pennsylvania | 164 | 6,776 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 6 | 406−1.3%/yr | −1.3%/yr | 2.60.6× | 0% | 340 in 2030−2.8%/yr |
| Hysterectomy, hysteroscopy & ablation |
Kidney stone management in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
| 2024 |
| 5,521 |
| 62% |
| 2025 est. | ≈ 350 | – |
| 2026 est. | ≈ 380 | – |
| 2022 | 10 | 478 | 56% |
| 2023 | 10 | 476 | 59% |
| 2024 | 11 | 5,521 | 62% |
| 2025 from claims | – | 348 319–368 | 63% |
| 2026 forecast | – | 385 339–444 | 63% |
| 2027 forecast | – | 419 358–499 | 64% |
| 2028 forecast | – | 455 380–557 | 64% |
| 2029 forecast | – | 494 404–620 | 65% |
| 2030 forecast | – | 537 430–688 | 65% |
In 2025, 100% hospital outpatient.
| −2%/yr |
| 5.0 |
| 12% |
| 6,810 in 2030+0.1%/yr |
| New Jersey | 109 | 6,001+1.1%/yr | +1.1%/yr | 5.8 | 31% | 7,770 in 2030+4.4%/yr |
| Massachusetts | 93 | 4,315−1.9%/yr | −1.9%/yr | 4.6 | 8% | 4,690 in 2030+1.4%/yr |
| Connecticut | 39 | 1,628−1.4%/yr | −1.4%/yr | 5.0 | 4% | 1,890 in 2030+2.5%/yr |
| New Hampshire | 22 | 921−1.3%/yr | −1.3%/yr | 4.1 | 2% | 1,150 in 2030+3.8%/yr |
| Rhode Island | 9 | 436−3.7%/yr | −3.7%/yr | 4.9 | 0% | 440 in 2030+0.3%/yr |
| Vermont | 10 | 397+2.4%/yr | +2.4%/yr | 3.5 | 0% | 810 in 2030+13%/yr |
| 3 |
| 290−6%/yr |
| −6%/yr |
| 2.00.6× |
| 7% |
| 370 in 2030+4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 2 | 101−14%/yr | −14%/yr | 0.60.3× | 0% | 40 in 2030−13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 82% of company spending on these surgeons in 2025, −12 pts on 2024.
In 2025, 3 companies reported engagement with Maine’s surgeons worth $7,272 in consulting, speaking, meals and travel tied to these products, about $661 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.